Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics (Nasdaq: SGMO) released new preliminary data from its Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. As of October 20, 2022, 13 patients have shown sustained, elevated levels of alpha-galactosidase A activity for over two years. Key findings include a 78% reduction in Gb3 substrate and a significant decrease in urine podocyte loss. The study is progressing towards a potential Phase 3 trial by the end of 2023. Furthermore, patients have demonstrated improved general health scores. This study may provide a transformative treatment option, reducing reliance on enzyme replacement therapy.
Sangamo Therapeutics (Nasdaq: SGMO) is set to host a conference call on February 22, 2023, at 4:30 p.m. ET to discuss its fourth quarter and full year 2022 financial results and business updates. Prior to this call, the company will release its financial results. Participants can register for the call using this link. An updated corporate presentation will also be available for review.
Sangamo Therapeutics (SGMO) reported its third quarter 2022 results, highlighting significant advancements in its clinical pipeline. The company announced promising preliminary data from the Phase 1/2 STAAR study for Fabry disease, resumed recruitment for the Phase 3 AFFINE trial for Hemophilia A, and continues dosing in various studies, including sickle cell and renal transplant rejection. Financially, SGMO posted a net loss of $53.2 million, with revenues of $26.5 million. Despite a decrease in revenues, the company narrowed its expense guidance for 2022, projecting total operating expenses between $315 million and $325 million.
Sangamo Therapeutics (NASDAQ: SGMO) announced it will release its third quarter 2022 financial results on November 3, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide business updates. Participants can register for the call through a provided link and are encouraged to join 10 minutes early. A replay will be available post-call.
Sangamo focuses on developing genomic medicines through gene therapy, cell therapy, and genome engineering.
Sangamo Therapeutics has provided updated results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease. As of July 21, 2022, nine patients exhibited elevated α-Gal A activity, showing up to a 30-fold increase for up to 23 months post-dosing. The therapy was well tolerated with no serious adverse events reported. The study has transitioned to an expansion phase, and the company is planning a Phase 3 trial. These results were presented at the ESGCT 2022 congress and suggest ST-920 could serve as an alternative to enzyme replacement therapy.
Sangamo Therapeutics (SGMO) announced updated results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for treating Fabry disease. As of February 14, 2022, the therapy showed general tolerability with no serious adverse events. Five patients exhibited sustained elevated α-Gal A activity levels, ranging from 3 to 17 times above normal for up to 15 months. The study has advanced to the dose expansion phase, and additional patients, including four who discontinued enzyme replacement therapy (ERT), have been dosed, with results expected later in 2022.
Sangamo Therapeutics (Nasdaq: SGMO) reported second quarter 2022 results, highlighting significant advances in its clinical programs. The company is progressing with its TX200 program for renal transplant rejection, now with Orphan Medicinal Product Designation from the European Commission. Revenues increased to $29.4 million, with a net loss of $43.2 million, an improvement from a net loss of $47.2 million in 2021. Total operating expenses decreased slightly to $75.1 million. The company maintains its financial guidance for total operating expenses for 2022.
Sangamo Therapeutics (NASDAQ: SGMO) has announced the release of its second quarter 2022 financial results, scheduled for August 4, 2022, after market close. A conference call to discuss these results will take place at 4:30 p.m. ET, open to the public. Participants are encouraged to register and join the call 10 minutes early for seamless access. A replay of the call will be available under the company's Events and Presentations section on its website, providing investors with insights into the company's financial performance and business developments.
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced that the European Commission has granted Orphan Medicinal Product Designation to TX200, a CAR-Treg therapy for solid organ transplantation. This designation aims to reduce transplant rejection and the burden of lifelong immunosuppressive therapy. The STEADFAST Phase 1/2 clinical study has already dosed the first patient in March 2022, with further dosing planned. TX200 is designed to prevent immune rejection in mismatched kidney transplants by promoting immunological tolerance, offering 10 years of market exclusivity upon approval.
Sangamo Therapeutics (Nasdaq: SGMO) announced its participation in key investor conferences in June and July 2022. The company will present at the Jefferies Healthcare Conference on June 9 at 9:00 a.m. ET and the Guggenheim I&I Spotlight Series focused on Treg-based therapies on July 12 at 2:45 p.m. ET. Access to presentations will be available on the company's website. Sangamo Therapeutics specializes in genomic medicines, utilizing innovative zinc finger technology to address treatment gaps for patients.